dexacortone
le vet beheer b.v., nīderlande - deksametazons - košļājamās tabletes - 0.5 mg - kaķi; suņi
tylogran
dopharma research b.v., nīderlande - aknas - granulas lietošanai ar dzeramo ūdeni/pienu - 1000 mg/g - cūkas; liellopi (teļi); tītari; vistas
otoxolan
krka, d.d., novo mesto, slovēnija - marbofloxacin, clotrimasolum, deksametazona acetātu - ausu pilieni, suspensija - suņi
dexamethason krka 40 mg tabletes
krka, d.d., novo mesto, slovenia - deksametazons - tablete - 40 mg
dexamethason krka 20 mg tabletes
krka, d.d., novo mesto, slovenia - deksametazons - tablete - 20 mg
dexamethason krka 4 mg tabletes
krka, d.d., novo mesto, slovenia - deksametazons - tablete - 4 mg
dexamethason krka 8 mg tabletes
krka, d.d., novo mesto, slovenia - deksametazons - tablete - 8 mg
dexametazona krka 4 mg tabletes
krka, d.d., novo mesto, slovenia - deksametazons - tablete - 4 mg
pepaxti
oncopeptides ab - melphalan flufenamide hydrochloride - multiple mieloma - antineoplastiski līdzekļi - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.